Abstracts tagged "gout"

Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 220 • 2015 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout
Tony R. Merriman¹, Murray Cadzow², Callum Tanner², Matthew A. Brown³, Katie Cremin⁴, Matthijs Janssen⁵, Tim Jansen⁶, Leo A. Joosten⁷, Timothy Radstake⁸, Philip L. Riches⁹, Anne-Kathrin Tausche¹⁰, Frederic Lioté¹¹, Alex So^12,13, Andre M. van Rij², Gregory T. Jones¹⁴, Lisa K. Stamp¹⁵, Nicola Dalbeth¹⁶ and Cushla McKinney², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ⁵Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁶P O Box 581, Haarlem, Netherlands, ⁷Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹¹Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹²Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹³Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁴Surgery, University of Otago, Dunedin, New Zealand, ¹⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁶Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Acute gouty arthritis results from an innate immune response to monosodium urate (MSU) crystals deposited in the joints and soft tissues of hyperuricaemic individuals.…
Abstract Number: 2027 • 2015 ACR/ARHP Annual Meeting
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Sara Bayat¹, Opetaia Aati², Juergen Rech¹, Alexander Cavallaro³, Michael Lell³, Elizabeth Araujo⁴, Christina Petsch⁴, Lisa K. Stamp⁵, Georg A. Schett⁶, Bernhard Manger¹ and Nicola Dalbeth², ¹Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁴Medical Department 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁶University of Erlangen-Nuremberg, Erlangen, Germany
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout Background/Purpose: Dual energy computed tomography (DECT) can visualize urate…
Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting
The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
Background/Purpose: Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
Abstract Number: 221 • 2015 ACR/ARHP Annual Meeting
Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study
Sirisha Mitnala¹, Amanda Phipps-Green², Christopher Franklin¹, Anne Horne³, Lisa K. Stamp⁴, Tony R. Merriman⁵ and Nicola Dalbeth^1,3, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Hyperuricaemia and secondary gout are well-recognised complications of diuretic use. Variants in ABCG2 and SLC2A9 have been identified as the two major genetic risk…
Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Jeewoong Choi¹, Na Lu², Yuqing Zhang³, Sharan K. Rai⁴, Gary C. Curhan⁵ and Hyon K. Choi², ¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³BUSM, Boston, MA, ⁴Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…
Abstract Number: 2351 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra Steinberg, Yun-Jung Choi, Robert Martin, Charles McWherter and Pol Boudes, Cymabay Therapeutics, Newark, CA
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) for the treatment of gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular…
Abstract Number: 180 • 2014 ACR/ARHP Annual Meeting
Analytical Comparison Between Point of Care Uric Acid Testing Meters
Jonathan Paraskos¹, Zsofia Berke², Jason Cook¹, Jeffrey N. Miner³, Martin Braddock¹, Adam Platt¹ and Glen Hughes¹, ¹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ²R&D, AstraZeneca, Mölndal, Sweden, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is a chronic, painful, debilitating form of arthritis resulting from elevated levels of serum uric acid (SUA), termed hyperuricemia. Hyperuricemia is caused by…
Abstract Number: 171 • 2014 ACR/ARHP Annual Meeting
High-Protein Diet (Atkins Diet) and Uric Acid Response
Na Lu¹, Iris Shai², Yuqing Zhang¹, Gary Curhan³ and Hyon K. Choi⁴, ¹Boston University School of Medicine, Boston, MA, ²Harvard School of Public Health, Boston, MA, ³German Research Center for Environmental Health, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose The conventional low-purine dietary approach to gout offers limited efficacy, palatability, and sustainability, and promotes increased consumption of refined carbohydrates and saturated fat that…
Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jasvinder A. Singh¹, Rekha Ramachandaran², Jie Zhang³, Fenglong Xie⁴, Shuo Yang⁵, Huifeng Yun⁶ and Jeffrey R. Curtis², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…
Abstract Number: 2962 • 2014 ACR/ARHP Annual Meeting
Association of the Toll-like Receptor 4 (TLR4) Gene with Gout
Humaira Rasheed¹, Ruth Topless¹, Richard Day², Diluk Kannangara³, Kenneth Williams³, Linda Bradbury⁴, Matthew Brown⁵, Catherine Hill⁶, Susan Lester⁷, Maureen Rischmueller⁸, Malcolm Smith⁹, Mariano Andrés¹⁰, Thomas Bardin¹¹, Michael Doherty¹², Matthijs Janssen¹³, Tim Jansen¹⁴, Leo Joosten¹⁵, Fernando Perez-Ruiz¹⁶, Timothy Radstake¹⁷, Philip L. Riches¹⁸, Ed Roddy¹⁹, Anne-Kathrin Tausche²⁰, Lisa K. Stamp²¹, Nicola Dalbeth²², Frederic Lioté²³, Alex So²⁴, Cushla McKinney¹ and Tony R. Merriman¹, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Dept of Clin Pharmacology, St. Vincent's Hospital, Sydney, Australia, ³University of New South Wales, Sydney, Australia, ⁴The University of Queensland, Brisbane, Australia, ⁵University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁸Department of Rheumatology, The Queen Elizabeth Hospital, SA, Australia, ⁹Rheumatology Unit Repatriation, Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Rheumatology Section, Hospital General Universitario de Alicante, Alicante, Spain, ¹¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ¹²Academic Rheumatology, City Hospital, Nottingham, United Kingdom, ¹³Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands, ¹⁴Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁵Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁶Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ¹⁷University Medical Center Utrecht, Utrecht, Netherlands, ¹⁸Centre for Rheumatic Diseases, University of Edinburgh, Edinburgh, United Kingdom, ¹⁹Research Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ²⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ²¹University of Otago, Christchurch, New Zealand, ²²Department of Medicine, University of Auckland, Auckland, New Zealand, ²³UFR médicale, Université Paris Diderot, Paris, France, ²⁴Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: Gout results from innate immune response to monosodium urate (MSU) crystals that form in the context of supersaturation of urate. Identification of genetic risk…
Abstract Number: 167 • 2014 ACR/ARHP Annual Meeting
Target Serum Urate: Do Patients Know Their Goal?
Brian W. Coburn¹, Kayli A. Bendlin², Harlan Sayles¹, Kathryn S. Hentzen³, Michaela M. Hrdy³ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy, Omaha VA Medical Center, Omaha, NE, ³Omaha VA Medical Center, Omaha, NE
Background/Purpose: Treat-to-target approaches are used to achieve therapeutic goals in conditions such as diabetes and rheumatoid arthritis. This strategy has also been widely endorsed in…
Abstract Number: 2963 • 2014 ACR/ARHP Annual Meeting
The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout results from chronic hyperuricemia. Most gout patients exhibit an increased renal reabsorption of uric acid which leads to elevated levels of serum uric…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
Abstract Number: 2176 • 2014 ACR/ARHP Annual Meeting
Macrophages-Mediated Response to Uric Acid Crystals Is Modulated By Their Functional Polarization
Emma Garcia-Melchor¹, Monica Guma², Jordi Yagüe¹, Manel Juan¹ and Jacquie Harper³, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Arthritis and Inflammation Group, Malaghan Institute of Medical Research, Wellington, New Zealand
Background/Purpose: Macrophages have been involved in both initiation and resolution of gout flares. Accordingly, these cells are characterized by their plasticity as the environment modulates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].